Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Biology of Blood and Marrow Transplantation Année : 2013

Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study.

Résumé

We report here the results of the GRAAPH-2003 trial with long-term follow-up in 45 patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Imatinib-based strategy improved the 4-year overall survival (OS) up to 52% versus 20% in the pre-imatinib LALA-94 trial (P = .0001). Despite the selection in patients who actually underwent transplantation, these results suggest that allogeneic or autologous stem cell transplants (SCTs) still have a place in overcoming the poor prognosis of Ph+ ALL in the era of imatinib therapy. OS was 50% after allogeneic SCT (24 patients), 33% in patients without a transplantation (9 patients), and 80% after autologous SCT (10 patients without allogeneic donor or >55 years, including 7 patients in complete molecular response).

Domaines

Cancer

Dates et versions

hal-00849684 , version 1 (31-07-2013)

Identifiants

Citer

Aline Tanguy-Schmidt, Philippe Rousselot, Yves Chalandon, Jean-Michel Cayuela, Sandrine Hayette, et al.. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study.. Biology of Blood and Marrow Transplantation, 2013, 19 (1), pp.150-5. ⟨10.1016/j.bbmt.2012.08.021⟩. ⟨hal-00849684⟩
1540 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More